Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.130
-0.010 (-0.47%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Oramed Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
87.01M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ORMP News
- 4 weeks ago - Oramed Pharmaceuticals Issues Letter to Shareholders - PRNewsWire
- 7 weeks ago - Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PRNewsWire
- 6 months ago - Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PRNewsWire
- 9 months ago - Oramed Letter to Shareholders - PRNewsWire
- 9 months ago - Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock - PRNewsWire
- 1 year ago - Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company - PRNewsWire
- 1 year ago - Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally - PRNewsWire
- 1 year ago - Oramed to Present at the 83rd American Diabetes Association Conference - PRNewsWire